Nothing Special   »   [go: up one dir, main page]

BR112015022197A8 - uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia - Google Patents

uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia Download PDF

Info

Publication number
BR112015022197A8
BR112015022197A8 BR112015022197A BR112015022197A BR112015022197A8 BR 112015022197 A8 BR112015022197 A8 BR 112015022197A8 BR 112015022197 A BR112015022197 A BR 112015022197A BR 112015022197 A BR112015022197 A BR 112015022197A BR 112015022197 A8 BR112015022197 A8 BR 112015022197A8
Authority
BR
Brazil
Prior art keywords
cataplexy
medicament
manufacture
compound
pharmaceutical composition
Prior art date
Application number
BR112015022197A
Other languages
English (en)
Other versions
BR112015022197A2 (pt
BR112015022197B1 (pt
Inventor
Bream Gary
A Khayrallah Moise
E Butts Stephen
Original Assignee
Aerial Biopharma Llc
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015022197(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerial Biopharma Llc, Sk Biopharmaceuticals Co Ltd filed Critical Aerial Biopharma Llc
Publication of BR112015022197A2 publication Critical patent/BR112015022197A2/pt
Publication of BR112015022197A8 publication Critical patent/BR112015022197A8/pt
Publication of BR112015022197B1 publication Critical patent/BR112015022197B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

treatment of cataplexy abstract the present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. _____________________________________________________ resumo patente de invenção: "tratamento de cataplexia". a presente invenção se refere a um método para o tratamento de cataplexia em um indivíduo com necessidade do mesmo, compreendendo administrar ao indivíduo a uma quantidade terapeuticamente eficaz de determinados compostos carbamato.
BR112015022197-1A 2013-03-13 2014-03-12 Uso de um composto para o tratamento de cataplexia BR112015022197B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
US61/778,998 2013-03-13
PCT/US2014/023969 WO2014164969A1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy

Publications (3)

Publication Number Publication Date
BR112015022197A2 BR112015022197A2 (pt) 2017-07-18
BR112015022197A8 true BR112015022197A8 (pt) 2019-11-26
BR112015022197B1 BR112015022197B1 (pt) 2022-06-07

Family

ID=51530017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022197-1A BR112015022197B1 (pt) 2013-03-13 2014-03-12 Uso de um composto para o tratamento de cataplexia

Country Status (22)

Country Link
US (6) US9359290B2 (pt)
EP (1) EP2968208B1 (pt)
JP (2) JP6530741B2 (pt)
KR (1) KR102192554B1 (pt)
CN (1) CN105431142B (pt)
AU (1) AU2014248849B2 (pt)
BR (1) BR112015022197B1 (pt)
CA (1) CA2905457A1 (pt)
DK (1) DK2968208T3 (pt)
ES (1) ES2927675T3 (pt)
HK (1) HK1219236A1 (pt)
HR (1) HRP20221018T1 (pt)
HU (1) HUE060060T2 (pt)
MX (1) MX2015012644A (pt)
MY (1) MY177740A (pt)
PH (1) PH12015502075A1 (pt)
PT (1) PT2968208T (pt)
RU (2) RU2019114940A (pt)
SG (1) SG11201507121RA (pt)
SI (1) SI2968208T1 (pt)
TW (2) TWI663971B (pt)
WO (1) WO2014164969A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101217949B (zh) * 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
EP2968208B1 (en) * 2013-03-13 2022-07-20 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy
WO2015010014A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
MY197630A (en) 2016-09-06 2023-06-29 Sk Biopharmaceuticals Co Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
SG11201903076QA (en) 2016-10-06 2019-05-30 Jazz Pharmaceuticals International Iii Ltd Carbamoyl phenylalaninol compounds and uses therof
JP2020528075A (ja) 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
US11413264B2 (en) 2017-07-31 2022-08-16 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途
US20210106522A1 (en) 2018-01-29 2021-04-15 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2020081461A1 (en) * 2018-10-15 2020-04-23 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
CN114746097A (zh) * 2019-12-03 2022-07-12 艾克萨姆治疗公司 瑞波西汀治疗神经系统障碍的用途
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
JPS58156351A (ja) * 1982-03-11 1983-09-17 Sumitomo Chem Co Ltd メタクリル酸合成触媒の再生方法
CZ285762B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015526A1 (en) 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
CN1960981A (zh) * 2004-03-31 2007-05-09 詹森药业有限公司 作为组胺h3受体调节剂的非咪唑杂环化合物
JP2008512386A (ja) * 2004-09-07 2008-04-24 オーファン メディカル，インコーポレイティド 改良型ｇｈｂ組成物
MX2007005172A (es) 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
CN101217949B (zh) * 2005-06-08 2012-10-17 爱思开生物制药株式会社 治疗睡眠-清醒病症
KR101335942B1 (ko) 2005-06-22 2013-12-04 에스케이바이오팜 주식회사 성기능 장애의 치료
BRPI0520451A2 (pt) 2005-07-26 2009-05-12 Janssen Pharmaceutica Nv métodos para tratamento de distúrbios associados a substáncias quìmicas
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
AU2007313017A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
JP2010510175A (ja) * 2006-11-10 2010-04-02 ディメリックス・バイオサイエンス・ピーティーワイ・リミテッド 甲状腺刺激ホルモン放出ホルモン受容体−オレキシン受容体のヘテロダイマー／オリゴマー
US8741950B2 (en) * 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
CN102762201B (zh) 2009-11-06 2013-12-18 爱思开生物制药株式会社 注意力缺陷/多动症的治疗方法
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
EP2968208B1 (en) * 2013-03-13 2022-07-20 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy

Also Published As

Publication number Publication date
BR112015022197A2 (pt) 2017-07-18
KR20150139522A (ko) 2015-12-11
CA2905457A1 (en) 2014-10-09
US20140275244A1 (en) 2014-09-18
US20190218174A1 (en) 2019-07-18
KR102192554B1 (ko) 2020-12-18
AU2014248849A1 (en) 2015-10-08
US20230416195A1 (en) 2023-12-28
MY177740A (en) 2020-09-23
US9359290B2 (en) 2016-06-07
AU2014248849B2 (en) 2018-08-30
US11072579B2 (en) 2021-07-27
HK1219236A1 (zh) 2017-03-31
TW201513856A (zh) 2015-04-16
RU2015143610A (ru) 2017-04-20
EP2968208A1 (en) 2016-01-20
US20220017457A1 (en) 2022-01-20
JP2019147830A (ja) 2019-09-05
TWI684450B (zh) 2020-02-11
TWI663971B (zh) 2019-07-01
EP2968208A4 (en) 2016-10-12
RU2019114940A3 (pt) 2019-12-25
RU2689984C2 (ru) 2019-05-30
WO2014164969A1 (en) 2014-10-09
CN105431142B (zh) 2019-04-26
EP2968208B1 (en) 2022-07-20
MX2015012644A (es) 2016-06-21
BR112015022197B1 (pt) 2022-06-07
CN105431142A (zh) 2016-03-23
SI2968208T1 (sl) 2023-02-28
PH12015502075B1 (en) 2016-01-18
JP6530741B2 (ja) 2019-06-12
RU2019114940A (ru) 2019-06-28
US20170137375A1 (en) 2017-05-18
PT2968208T (pt) 2022-10-28
HUE060060T2 (hu) 2023-01-28
HRP20221018T1 (hr) 2023-01-06
JP2016512531A (ja) 2016-04-28
PH12015502075A1 (en) 2016-01-18
DK2968208T3 (da) 2022-08-22
US20160250176A1 (en) 2016-09-01
US10259780B2 (en) 2019-04-16
RU2015143610A3 (pt) 2018-03-21
TW201919606A (zh) 2019-06-01
US9585863B2 (en) 2017-03-07
US11713292B2 (en) 2023-08-01
ES2927675T3 (es) 2022-11-10
SG11201507121RA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
MX2013003635A (es) Compuestos de n-heteroarilo.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
TW201613578A (en) Pharmaceutical combinations
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
EA201591180A1 (ru) Составы ингибитора lfa-1
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
BR112018002763A2 (pt) método para cicatrização de ferimentos
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
BR112015030734A2 (pt) produto farmacêutico, kit e método de tratamento
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR) ; JAZZ PHARMACEUTICALS IRELAND LIMITED (IE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2014, OBSERVADAS AS CONDICOES LEGAIS